minimal residual disease: a key determinant of all treatment response
Published 6 years ago • 195 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:47
the importance of minimal residual disease in all
-
3:28
bringing minimal residual disease (mrd) measurement to the clinic
-
1:50
treatment of minimal residual disease in aml patients
-
5:19
circulating micrornas as mrd biomarkers in pediatric all
-
3:19
what impact have new minimal residual disease (mrd) assessment techniques had in myeloma?
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
0:50
remaining questions on bone marrow assessment of minimal residual disease
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
7:39
understanding mrd
-
4:35
flow cytometry animation
-
3:40
what’s new in minimal residual disease (mrd) detection in myeloma?
-
1:39
minimal residual disease (mrd) monitoring for multiple myeloma is here to stay
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:02
challenges with measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
2:18
the utility of measurable residual disease (mrd) assessment in acute myeloid leukemia (aml)
-
1:41
novel technologies to detect minimal residual disease (mrd)
-
2:35
mrd focus: why measurable residual disease testing is the future
-
2:22
next-generation methodologies: the future for mrd monitoring in all?
-
2:51
profiling deep minimal residual disease in multiple myeloma
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
3:07
minimal residual disease (mrd)